Veterinary Specialty Hospital, San Diego is excited to announce a new clinical trial for dogs with lymphoma.
Lymphoma, the most common hematopoietic tumor of dogs, is an aggressive disease. While the majority of dogs will respond to cytotoxic chemotherapy utilizing a standard multi-agent (e.g. CHOPbased) approach, greater than 95% of dogs will relapse.
This study will evaluate the safety and efficacy of TANOVEA®-CA1 when combined with doxorubicin in dogs with untreated lymphoma. TANOVEA-CA1 received conditional approval for the treatment of canine lymphoma, which means that when used according to the label, the drug is safe and has a “reasonable expectation of effectiveness” for treating lymphoma in dogs. This study may provide information on a multi-drug treatment protocol that may result in improved outcomes for dogs with multicentric lymphoma.
- Dogs with lymphoma who have not been previously treated
- Dogs must be at least 1 year old, otherwise healthy, and have adequate organ function
- West Highland White Terrier Breed is excluded from the study
• TANOVEA-CA1 is provided at no cost
The other costs associated with treatment, including staging and treatment with doxorubicin are the owner’s responsibility.
- Veterinary Specialty Hospital, Sorrento Valley, San Diego, CA
If you have a client interested in participating in this study, please refer the patient VSH, Sorrento Valley or submit your questions below.